Natco Pharma announces launch of first generic of top selling cancer drug Revlimid

Revlimid had annual sales of $2.3 billion as of December 2021, according to IQVIA data. The generic version of Revlimid will be available in 5mg, 10mg, 15mg, and 25mg strengths. The announcement came after market hours. The Shares of Natco Pharma 2.98% to close at Rs 844.30 on BSE on Monday, the benchmark Sensex fell 2.74% to end at 52,842.75 points.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jD6MWKr
via IFTTT